Mbal Lyulin EAD
- Address
- lock Available on a paid plan
MBAL Lyulin EAD - Rheumatology and Metabolic Disorders Research Center
MBAL Lyulin EAD is a distinguished clinical research facility specializing in autoimmune and inflammatory conditions, with particular expertise in rheumatological disorders and metabolic diseases. The center has established itself as a key contributor to advancing treatment options for patients with complex chronic conditions, participating in pivotal international trials evaluating novel biologics, biosimilars, and innovative therapeutic agents.
- Psoriatic Arthritis - Multiple trials investigating biologics including guselkumab, sonelokimab, and JNJ-77242113 for treatment-naive and biologic-experienced patients
- Rheumatoid Arthritis - Studies evaluating filgotinib, AP1189, and etanercept biosimilars in various patient populations
- Severe Hypertriglyceridemia - Clinical trials assessing pegozafermin and plozasiran for lipid management
- Progressive Multiple Sclerosis and other inflammatory conditions - Trials exploring IMU-838 and additional therapeutic modalities
The center demonstrates comprehensive capabilities across diverse therapeutic areas, including studies in osteoporosis, venous thromboembolism prevention, and endometriosis-related pain management. MBAL Lyulin EAD's research portfolio reflects a commitment to both early-phase dose-finding studies and late-phase efficacy trials, with significant focus on comparative effectiveness research and long-term safety evaluations of emerging treatments in rheumatology and metabolic medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1MoonLake Immunotherapeutics AG2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mbal Lyulin EAD
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sonelokimab | 3 | Unknown | 2025-03-25 | 2025-03-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.